PMID- 21713319
OWN - NLM
STAT- MEDLINE
DCOM- 20120109
LR  - 20220311
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 106
IP  - 2
DP  - 2011 Aug
TI  - Involvement of microparticles in diabetic vascular complications.
PG  - 310-21
LID - 10.1160/TH10-11-0712 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is associated with increased coagulability and 
      vascular complications. Circulating microparticles (MPs) are involved in 
      thrombosis, inflammation, and angiogenesis. However, the role of MPs in T2DM 
      vascular complications is unclear. We characterised the cell origin and 
      pro-coagulant profiles of MPs obtained from 41 healthy controls and 123 T2DM 
      patients with coronary artery disease, retinopathy and foot ulcers. The effects 
      of MPs on endothelial cell coagulability and tube formation were evaluated. 
      Patients with severe diabetic foot ulcers expressed the highest levels of MPs 
      originated from platelet and endothelial cells and negatively-charged 
      phospholipid-bearing MPs. MP coagulability, calculated from MP tissue factor (TF) 
      and TF pathway inhibitor (TFPI) ratio, was low in healthy controls and in 
      diabetic retinopathy patients (<0.7) but high in patients with coronary artery 
      disease and foot ulcers (>1.8, p>/=0.002). MPs of all T2DM patients induced a more 
      than two-fold increase in endothelial cell TF (antigen and gene expression) but 
      did not affect TFPI levels. Tube networks were longest and most stable in 
      endothelial cells that were incubated with MPs of healthy controls, whereas no 
      tube formation occurred in MPs of diabetic patients with coronary artery disease. 
      MPs of diabetic retinopathy and diabetic foot ulcer patients induced branched 
      tube networks that were unstable and collapsed over time. This study demonstrates 
      that MP characteristics are related to the specific type of vascular 
      complications and may serve as a bio-marker for the pro- coagulant state and 
      vascular pathology in patients with T2DM.
FAU - Tsimerman, Gala
AU  - Tsimerman G
AD  - Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
FAU - Roguin, Ariel
AU  - Roguin A
FAU - Bachar, Anat
AU  - Bachar A
FAU - Melamed, Eyal
AU  - Melamed E
FAU - Brenner, Benjamin
AU  - Brenner B
FAU - Aharon, Anat
AU  - Aharon A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110628
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Lipoproteins)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 9035-58-9 (Thromboplastin)
SB  - IM
MH  - Aged
MH  - Blood Coagulation
MH  - Case-Control Studies
MH  - Cell-Derived Microparticles/pathology/*physiology
MH  - Coronary Artery Disease/blood/etiology
MH  - Diabetes Mellitus, Type 2/complications
MH  - Diabetic Angiopathies/blood/*etiology
MH  - Diabetic Foot/blood/etiology
MH  - Diabetic Retinopathy/blood/etiology
MH  - Endothelial Cells/pathology/physiology
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Lipoproteins/genetics/physiology
MH  - Male
MH  - Middle Aged
MH  - Neovascularization, Pathologic
MH  - Platelet Activation
MH  - Thromboplastin/genetics/physiology
EDAT- 2011/06/30 06:00
MHDA- 2012/01/10 06:00
CRDT- 2011/06/30 06:00
PHST- 2010/11/14 00:00 [received]
PHST- 2011/05/16 00:00 [accepted]
PHST- 2011/06/30 06:00 [entrez]
PHST- 2011/06/30 06:00 [pubmed]
PHST- 2012/01/10 06:00 [medline]
AID - 10-11-0712 [pii]
AID - 10.1160/TH10-11-0712 [doi]
PST - ppublish
SO  - Thromb Haemost. 2011 Aug;106(2):310-21. doi: 10.1160/TH10-11-0712. Epub 2011 Jun 
      28.